Screener
Insulet PODD International — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Insulet’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001145197-26-000169
| (in millions) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| U.S. | $549.9 | $463.3 | $1,068.8 | $879.9 |
| International | 251.8 | 185.8 | 494.6 | 338.1 |
| Total revenue | $801.7 | $649.1 | $1,563.4 | $1,218.1 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Insulet's international — revenue?
- Insulet (PODD) reported international — revenue of $251.8M in Q2 2026.
- How has Insulet's international — revenue changed year-over-year?
- Insulet's international — revenue increased by 35.5% year-over-year, from $185.8M to $251.8M.
- What is the long-term trend for Insulet's international — revenue?
- Over 4 years (2021 to 2025), Insulet's international — revenue has grown at a 20.3% compound annual growth rate (CAGR), from $359.9M to $754.3M.
- What does international — revenue mean?
- This metric represents the total net sales generated from the sale of insulin delivery systems and related supplies within geographic regions outside of the company's primary domestic market. It reflects the company's success in expanding its global footprint and penetrating international healthcare systems. Monitoring this figure helps investors assess the scalability of the business model across diverse regulatory and reimbursement environments.
Ask your AI about Insulet's international — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude